Sandoz Files Biosimilar Neulasta In Europe, Praises EMA
This article was originally published in Scrip
Executive Summary
Sandoz, Novartis AG's generic drugs unit, has confirmed it has filed a market authorization application in Europe for a biosimilar version of Amgen Inc.'s Neulasta (pegfilgrastim) – the company also praised biosimilar registration processes at the EMA.
You may also be interested in...
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.